Translating condensate biology into medicine.
Dewpoint Therapeutics is the leading biotech company applying the biology of biomolecular condensates to drug discovery and development. Using its AI/ML-enabled ERSA platform, Dewpoint is building a pipeline of first-in-class condensate modulators (c-mods) targeting oncology, neurodegenerative, cardiopulmonary, and metabolic diseases, with strategic collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2025
Feb 2022
Sep 2020
Jan 2019
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.
